Annovis Bio, Inc. Files 8-K for Material Definitive Agreement
Ticker: ANVS · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $1.50, $1.4999, $0, $6.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) signed a big deal on Oct 10th. 8-K filed.
AI Summary
On October 10, 2025, Annovis Bio, Inc. entered into a material definitive agreement. The company, previously known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new agreement for Annovis Bio, Inc., which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-39202 — SEC File Number (Identifies the company's filing with the SEC)
- 26-2540421 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former Company Name
- October 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Malvern, PA (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement Annovis Bio, Inc. entered into?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 10, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 10, 2025.
What is Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
Where are Annovis Bio, Inc.'s principal executive offices located?
Annovis Bio, Inc.'s principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,380 words · 6 min read · ~5 pages · Grade level 12.3 · Accepted 2025-10-14 17:19:23
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
- $1.50 — s." The offering price of each Share is $1.50 per share. The offering price of each P
- $1.4999 — ing price of each Pre-Funded Warrant is $1.4999 (equal to the offering price per Share,
- $0 — to the offering price per Share, minus $0.0001, the exercise price of each Pre-Fu
- $6.0 m — fering are expected to be approximately $6.0 million, before deducting offering expens
- $50,000 — ss proceeds from the Offering and up to $50,000 for reasonable and documented fees and
- $10,000 — and for its clearing expenses of up to $10,000. Pursuant to the Engagement Letter, th
- $2.20 — rcisable and an exercise price equal to $2.20 per share. The Placement Agent Warrants
Filing Documents
- tm2528502d2_8k.htm (8-K) — 37KB
- tm2528502d2_ex4-1.htm (EX-4.1) — 93KB
- tm2528502d2_ex4-2.htm (EX-4.2) — 96KB
- tm2528502d2_ex5-1.htm (EX-5.1) — 14KB
- tm2528502d2_ex10-1.htm (EX-10.1) — 205KB
- tm2528502d2_ex10-2.htm (EX-10.2) — 26KB
- tm2528502d2_ex99-1.htm (EX-99.1) — 8KB
- tm2528502d2_ex5-1img01.jpg (GRAPHIC) — 5KB
- 0001104659-25-099356.txt ( ) — 766KB
- anvs-20251010.xsd (EX-101.SCH) — 3KB
- anvs-20251010_lab.xml (EX-101.LAB) — 33KB
- anvs-20251010_pre.xml (EX-101.PRE) — 22KB
- tm2528502d2_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Description Exhibit Number 4.1 Form of Pre-Funded Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Loeb & Loeb LLP 10.1 Securities Purchase Agreement, dated October 10, 2025 10.2 Form of Lock-Up Agreement 23.1 Consent of Loeb & Loeb LLP (contained in Exhibit 5.1) 99.1 Press Release dated October 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: October 14, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer